Taking people in SpainPhase 2
Long-term safety follow-up of people treated with modified T cells
Follows people previously given Autolus CAR T cell therapy for possible long-term cancer risk.
Key facts
- Who runs it
- Autolus Limited
- Where
- Barcelona, Madrid, and Valencia, SpainSee the 3 sites
- Trial code
- Registry title
- Long-term follow-up of patients previously treated with autologous T cells genetically modified with viral vectors.
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 21 people, planned
- Started
- 1 Sept 2025
- Expected to end
- 21 Nov 2039
- Type of study
- Interventional
- Record updated
- 18 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people who already had an AUTO CAR T cell therapy in an earlier study. It follows them over a long time to check safety.
- Sex
- All sexes can join.
- Earlier treatment
- People must have received an AUTO CAR T cell therapy in a previous treatment study.
Main reasons for not taking part
- The record lists no exclusion criteria.
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Patients must have received an AUTO CAR T cell therapy on a previous treatment study
- Patients must have provided informed consent for long-term follow-up study prior to participation
- Patients must be able to comply with the study requirements
Who cannot take part
- There are no exclusion criteria for this study
Where in Spain
- Hospital Universitari Vall d'HebronBarcelona, SpainTaking people
- Hospital Infantil Universitario Nino JesusMadrid, SpainTaking people
- Hospital Universitario Y Politecnico La FeValencia, SpainTaking people
About the trial
What the trial wants to find out
Long-term safety
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- Long-term follow-up of patients previously treated with autologous T cells genetically modified with viral vectors.
- Plain-language title
- Long-term safety follow-up of people treated with modified T cellsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 18 March 2026